Precision treatment in advanced hepatocellular carcinoma

被引：93
作者：
Yang, Xupeng [1 ,2 ]
Yang, Chen [3 ,4 ]
Zhang, Shu [1 ,2 ]
Zhu, Andrew X. [5 ,6 ]
Geng, Haigang [3 ]
Bernards, Rene [7 ]
Qin, Wenxin [3 ]
Fan, Jia [1 ]
Wang, Cun [3 ]
Gao, Qiang [1 ,2 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat,Key Lab Carcinogene, Shanghai, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Key Lab Med Epigenet & Metab, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Syst Med Canc, Shanghai 200032, Peoples R China
[4] German Canc Res Ctr, Immune Regulat Canc Grp, Heidelberg, Germany
[5] I Mab Biopharm, Shanghai, Peoples R China
[6] Jiahui Int Canc Ctr, Jiahui Hlth, Shanghai, Peoples R China
[7] Netherlands Canc Inst, Oncode Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands
来源：
CANCER CELL | 2024年 / 42卷 / 02期
关键词：
PATIENT-DERIVED ORGANOIDS; 1ST-LINE TREATMENT; MOLECULAR CLASSIFICATION; OPEN-LABEL; NEOANTIGEN VACCINE; TARGETED THERAPY; NON-INFERIORITY; GROWTH-FACTOR; DOUBLE-BLIND; SORAFENIB;
D O I：
10.1016/j.ccell.2024.01.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the unique molecular characteristics of individual patient to personalize treatment modalities, aiming to maximize therapeutic efficacy while minimizing side effects. Although precision treatment has shown significant success in multiple cancer types, its application in HCC remains in its infancy. In this review, we discuss key aspects of precision treatment in HCC, including therapeutic biomarkers, molecular classifications, and the heterogeneity of the tumor microenvironment. We also propose future directions, ranging from revolutionizing current treatment methodologies to personalizing therapy through functional assays, which will accelerate the next phase of advancements in this area.
引用
收藏
页码：180 / 197
页数：18
相关论文
共 188 条
  • [1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 54 - 63
  • [2] Abou-Alfa Ghassan K, 2022, NEJM Evid, V1, pEVIDoa2100070, DOI 10.1056/EVIDoa2100070
  • [3] PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
    Adhikari, Bikash
    Bozilovic, Jelena
    Diebold, Mathias
    Schwarz, Jessica Denise
    Hofstetter, Julia
    Schroeder, Martin
    Wanior, Marek
    Narain, Ashwin
    Vogt, Markus
    Dudvarski Stankovic, Nevenka
    Baluapuri, Apoorva
    Schoenemann, Lars
    Eing, Lorenz
    Bhandare, Pranjali
    Kuster, Bernhard
    Schlosser, Andreas
    Heinzlmeir, Stephanie
    Sotriffer, Christoph
    Knapp, Stefan
    Wolf, Elmar
    [J]. NATURE CHEMICAL BIOLOGY, 2020, 16 (11) : 1179 - +
  • [4] Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
    Ally, Adrian
    Balasundaram, Miruna
    Carlsen, Rebecca
    Chuah, Eric
    Clarke, Amanda
    Dhalla, Noreen
    Holt, Robert A.
    Jones, Steven J. M.
    Lee, Darlene
    Ma, Yussanne
    Marra, Marco A.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Andrew J.
    Schein, Jacqueline E.
    Sipahimalani, Payal
    Tam, Angela
    Thiessen, Nina
    Cheung, Dorothy
    Wong, Tina
    Brooks, Denise
    Robertson, A. Gordon
    Bowlby, Reanne
    Mungall, Karen
    Sadeghi, Sara
    Xi, Liu
    Covington, Kyle
    Shinbrot, Eve
    Wheeler, David A.
    Gibbs, Richard A.
    Donehower, Lawrence A.
    Wang, Linghua
    Bowen, Jay
    Gastier-Foster, Julie M.
    Gerken, Mark
    Helsel, Carmen
    Leraas, Kristen M.
    Lichtenberg, Tara M.
    Ramirez, Nilsa C.
    Wise, Lisa
    Zmuda, Erik
    Gabriel, Stacey B.
    Meyerson, Matthew
    Cibulskis, Carrie
    Murray, Bradley A.
    Shih, Juliann
    Beroukhim, Rameen
    Cherniack, Andrew D.
    Schumacher, Steven E.
    Saksena, Gordon
    [J]. CELL, 2017, 169 (07) : 1327 - +
  • [5] Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998
  • [6] Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
    Awad, Mark M.
    Govindan, Ramaswamy
    Balogh, Kristen N.
    Spigel, David R.
    Garon, Edward B.
    Bushway, Meghan E.
    Poran, Asaf
    Sheen, Joong Hyuk
    Kohler, Victoria
    Esaulova, Ekaterina
    Srouji, John
    Ramesh, Suchitra
    Vyasamneni, Rohit
    Karki, Binisha
    Sciuto, Tracey E.
    Sethi, Himanshu
    Dong, Jesse Z.
    Moles, Melissa A.
    Manson, Kelledy
    Rooney, Michael S.
    Khondker, Zakaria S.
    DeMario, Mark
    Gaynor, Richard B.
    Srinivasan, Lakshmi
    [J]. CANCER CELL, 2022, 40 (09) : 1010 - +
  • [7] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [8] Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses
    Blum, Steven M.
    Rouhani, Sherin J.
    Sullivan, Ryan J.
    [J]. IMMUNOLOGICAL REVIEWS, 2023, 318 (01) : 167 - 178
  • [9] Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
    Boyault, Sandrine
    Rickman, David S.
    de Reynies, Aurelien
    Balabaud, Charles
    Rebouissou, Sandra
    Jeannot, Emmanuelle
    Herault, Aurelie
    Saric, Jean
    Belghiti, Jacques
    Franco, Dominique
    Bioulac-Sage, Paulette
    Laurent-Puig, Pierre
    Zucman-Rossi, Jessica
    [J]. HEPATOLOGY, 2007, 45 (01) : 42 - 52
  • [10] Human primary liver cancer-derived organoid cultures for disease modeling and drug screening
    Broutier, Laura
    Mastrogiovanni, Gianmarco
    Verstegen, Monique M. A.
    Francies, Hayley E.
    Gavarro, Lena Morrill
    Bradshaw, Charles R.
    Allen, George E.
    Arnes-Benito, Robert
    Sidorova, Olga
    Gaspersz, Marcia P.
    Georgakopoulos, Nikitas
    Koo, Bon-Kyoung
    Dietmann, Sabine
    Davies, Susan E.
    Praseedom, Raaj K.
    Lieshout, Ruby
    IJzermans, Jan N. M.
    Wigmore, Stephen J.
    Saeb-Parsy, Kourosh
    Garnett, Mathew J.
    van der Laan, Luc J. W.
    Huch, Meritxell
    [J]. NATURE MEDICINE, 2017, 23 (12) : 1424 - +
12345678910